164 results
Page 2 of 9
8-K
EX-99.1
zu5 pg1emlo8
30 Nov 21
TG Therapeutics Provides Regulatory Update
7:59am
8-K
EX-99.1
8jpsig4a50j5fj
4 Nov 21
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
7:27am
8-K
EX-99.1
pv12dkkbkfrx
2 Aug 21
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
7:12am
8-K
EX-99.1
ad0e dctzzqy6kb3z
10 May 21
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
7:23am
8-K
EX-99.1
w5j2a3cw
16 Apr 21
Other Events
7:53am
8-K
EX-99.1
cowe74 q3th
2 Mar 21
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
7:07am
8-K
EX-99.1
ur1uozhwb ux9rflpic
8 Feb 21
UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen
7:01am
424B5
6g2a5 br2pjesqsmpd9
16 Dec 20
Prospectus supplement for primary offering
4:11pm
424B5
j519eywj
14 Dec 20
Prospectus supplement for primary offering
8:09am
8-K
EX-99.1
8myn dnko3iopijoqj
10 Dec 20
Other Events
7:50am
8-K
EX-99.2
6xsuuwn
8 Dec 20
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
8:00am
8-K
EX-99.1
ylo3u4
8 Dec 20
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
8:00am
8-K
pg1o1xq0 9fop7
8 Dec 20
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
8:00am
8-K
EX-99.1
ou33 43mj0c7h9
9 Nov 20
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
5:29pm